Related Experiment Videos
Drug-induced apnea
1Inserm U272, Université de Nancy I, France.
Biology of the Neonate
|January 1, 1994
Summary
Certain medications can cause apnea, or pauses in breathing, in developing children. This risk is higher in infants and neonates due to their unique vulnerabilities to drug-induced respiratory depression.
Area of Science:
- Pediatric Pharmacology
- Neonatal Medicine
- Respiratory Physiology
Background:
- Medications pose a significant risk of inducing apnea in neonates, infants, and children.
- Children exhibit heightened vulnerability to respiratory disorders during developmental stages.
- Drug dosages safe for adults can be detrimental to younger subjects.
Purpose of the Study:
- To review drugs that induce apnea in pediatric populations.
- To elucidate the mechanisms of drug-induced apnea during child development.
- To highlight the risks associated with various pharmacological classes.
Main Methods:
- Literature review of drug-induced apnea in pediatric patients.
- Analysis of pharmacological agents implicated in respiratory depression.
- Examination of developmental vulnerabilities and pathogenetic mechanisms.
Main Results:
- Sedatives and hypnotics (phenothiazines, barbiturates, benzodiazepines, anesthetics) are primary culprits, accounting for over half of cases.
- Other implicated drug classes include analgesics, neuromuscular agents, and cardiovascular drugs.
- Drug-induced apnea results from disruption of respiratory control mechanisms (medullary centers, CNS, sleep, airways, muscles).
Conclusions:
- Drug-induced apnea is a critical concern throughout pediatric development, particularly in neonates and infants.
- The specific sensitivities of developing respiratory systems amplify drug risks.
- Understanding these risks is crucial for preventing unexpected respiratory events in children.